ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 9.190-9.690 for the period, compared to the consensus EPS estimate of 9.100. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ANIP shares. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Canaccord Genuity Group began coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They set a “hold” rating and a $91.00 target price for the company. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Guggenheim reissued a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $106.83.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $78.25 on Friday. ANI Pharmaceuticals has a 52 week low of $70.15 and a 52 week high of $99.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm’s 50-day simple moving average is $81.02 and its 200 day simple moving average is $79.37. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of 19.81 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the previous year, the firm posted $1.80 EPS. The business’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts predict that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director directly owned 38,432 shares of the company’s stock, valued at $3,098,772.16. The trade was a 20.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction on Monday, July 13th. The shares were sold at an average price of $81.84, for a total value of $40,920.00. Following the sale, the vice president owned 77,390 shares of the company’s stock, valued at approximately $6,333,597.60. The trade was a 0.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 88,029 shares of company stock valued at $6,954,472 in the last quarter. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals News Roundup

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Maryland State Retirement & Pension System lifted its stake in shares of ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after purchasing an additional 134 shares during the period. CANADA LIFE ASSURANCE Co grew its stake in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after purchasing an additional 198 shares during the period. Federation des caisses Desjardins du Quebec grew its stake in ANI Pharmaceuticals by 0.6% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after purchasing an additional 221 shares during the period. Amundi grew its stake in ANI Pharmaceuticals by 1.2% during the third quarter. Amundi now owns 23,918 shares of the specialty pharmaceutical company’s stock worth $2,202,000 after purchasing an additional 285 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in ANI Pharmaceuticals by 1.5% in the third quarter. Alliancebernstein L.P. now owns 20,310 shares of the specialty pharmaceutical company’s stock worth $1,860,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.